1
|
Barbaglia G, Robles N, Hilarión P, Torres M, Gotsens M, Colell E, Puigdomènech E, de la Torre JA, Espallargues M. Integrated health and social care evaluation framework for mental health and drug addiction care. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac130.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Guiding the decision-making process in mental health investments is advisable. The objective of the study is to develop a framework for evaluating the quality of integrated health and social care in Mental Health and Drug Addiction (MH&DA)
Methods
A literature review helped to establish a definition of integrated care specific to MH&DA and to identify potential indicators for its evaluation. The quality of integrated care was assessed through focus groups (FGs) and interviews (INs) with three different profiles: professionals (2FGs & 2 INs), patients (3 FGs & 2 INs) and families/carers (2FGs & 2 INs). Additional indicators were also obtained from them.
Results
Out of 2,226 publications identified, 87 (4%) were reviewed in full. According to the literature, integrated care in MH&DA is based on four main components: case management, comprehensive assessment, individualised care plan and care coordination among different providers. Based on these components, an operational definition of integrated care was developed and validated in the FGs and INs. Positive aspects identified were a respectful approach and positive experiences of coordination between social and community network. Regarding indicators about 400 were identified, after screening were reduced to 60: 25% corresponded to accessibility, 20% person-centred care, 16% each to care coordination and to effectiveness. In general, the main threats to the quality of care, identified in FGs and INs, matched the dimensions with the highest proportion of indicators (i.e., limited care resources, poor coordination and communication among professionals and services, and barriers in accessing specialized treatment).
Conclusions
According to literature, integrated care in MH&DA seems to be mainly evaluated in terms of accessibility and person-centred care. In a following phase, a large group of experts will be key to select the most relevant dimensions and indicators for the evaluation in a Delphi study.
Key messages
Collapse
Affiliation(s)
- G Barbaglia
- Universitat Pompeu Fabra , Barcelona, Spain
- Agència de Salut Publica de Barcelona , Barcelona, Spain
- Red Investigación en Atención de Adicciones, Spain
| | - N Robles
- eHealth Center, Universitat Oberta de Catalunya , Catalunya, Spain
| | - P Hilarión
- Fundación Avedis Donabedian , Barcelona, Spain
| | - M Torres
- Agència de Qualitat i Avaluació de Catalunya , Catalunya, Spain
| | - M Gotsens
- Agència de Salut Publica de Barcelona , Barcelona, Spain
| | - E Colell
- Consorci Sanitari de Barcelona , Barcelona, Spain
| | - E Puigdomènech
- Agència de Salut Publica de Barcelona , Barcelona, Spain
- Universidad de León , León, Spain
| | | | - M Espallargues
- Agència de Qualitat i Avaluació de Catalunya , Catalunya, Spain
| |
Collapse
|
2
|
Arias de la Torre J, Ronaldson A, Vilagut G, Peters M, Valderas JM, Serrano-Blanco A, Martín V, Dregan A, Alonso J. Prevalence of Major Depressive Episode in 27 European Countries. Eur J Public Health 2021. [DOI: 10.1093/eurpub/ckab164.391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Information about the prevalence of current Major Depressive Episode (MDE) across European countries is essential for its monitoring and for the development of evidence- based mental health policies. The aims were to: 1) estimate the prevalence of MDE by country in Europe; and 2) assess variations in prevalence between countries.
Methods
Data from participants of 27 countries that completed the questionnaire of the second wave of the European Health Interview Survey (EHIS-2) were analysed (n = 258,888). The prevalence of MDE was quantified using the Patient Health Questionnaire-8 (PHQ-8) with a cut-off score of ≥ 10. Prevalence and 95% Confidence Intervals (CI) were estimated for each country. Variation in prevalence (country vs the rest) was evaluated using bivariable and multivariable negative binomial regression models considering the specific country as the main explanatory variable. From these models, crude Prevalence Ratios (PR) and adjusted Prevalence Ratios (aPR) were obtained.
Results
The overall prevalence of current MDE in Europe was 6.38% (6.24%-6.52%). The country with the lowest prevalence was the Czech Republic (2.58%, 2.14%-3.02%) and the country with highest prevalence Iceland (10.33%, 9.33%-11.32%). In all the countries (except for Finland and Croatia) prevalence was higher in women than in men. The countries with the highest aPR were Germany (aPR: 1.80, 95% CI: 1.71-1.89) and Luxembourg (aPR: 1.50, 95% CI: 1.35-1.66), while Slovakia (aPR: 0.28, 95% CI: 0.24-0.33) and the Czech Republic (aPR: 0.32, 95% CI: 0.27-0.38) exhibited the lowest aPR.
Conclusions
Considerable variability in the prevalence of MDE by country in Europe was observed without a clear pattern. These results serve as baseline for monitoring the prevalence of MDE at a European level and suggest a need for developing preventive strategies against depression, particularly in those countries identified with the highest prevalence.
Key messages
The results of this study show that the overall prevalence of MDE is high (6.38%), with important variation across countries (ranging from 2.58% in the Czech Republic to 10.33% in Iceland). The results found could serve as a reference for the monitoring of MDE in Europe and for the development of screening and preventive strategies both at European level as well as at a country level.
Collapse
Affiliation(s)
- J Arias de la Torre
- Psychological Medicine, King's College London, London, UK
- CIBERESP, Madrid, Spain
- Universidad de León, León, Spain
| | - A Ronaldson
- Psychological Medicine, King's College London, London, UK
| | - G Vilagut
- CIBERESP, Madrid, Spain
- Hospital del Mar Medical Research Institute, Barcelona, Spain
| | - M Peters
- University of Oxford, Oxford, UK
| | | | - A Serrano-Blanco
- CIBERESP, Madrid, Spain
- Parc Sanitari Sant Joan de Deu, Sant Boi del Llobregat, Spain
| | - V Martín
- CIBERESP, Madrid, Spain
- Universidad de León, León, Spain
| | - A Dregan
- Psychological Medicine, King's College London, London, UK
| | - J Alonso
- CIBERESP, Madrid, Spain
- Hospital del Mar Medical Research Institute, Barcelona, Spain
- Pompeu Fabra University, Barcelona, Spain
| |
Collapse
|
3
|
Arias de la Torre J, Ronaldson A, Valderas JM, JAlonso, Prina M, Hatch S, Rayner L, Pickles A, Hotopf M, ADregan. Depression and physical multimorbidity during the adulthood. Cross-sectional associations. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa165.824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The prevalence of depression and physical multimorbidity (pMM) might vary over the life course in a non-random fashion. The aims of our study were to: 1) assess the prevalence of depression and pMM over the life course; and 2) estimate changes in their pattern of association at different ages.
Methods
Data from 13,736 participants aged 26, 30, 34, 38, 42 and 46 years old of the British Child Study cohort was used. Individuals with information on current self-reported depression were selected as study sample. pMM (yes/no) caseness was defined as the coexistence of 2 or more self-reported physical conditions (e.g. asthma, diabetes, epilepsy). The prevalence of depression and pMM was calculated for each wave. To assess their relationship, prevalence ratios (PR) adjusted by gender, socioeconomic (e.g. educational level) and health-related variables (e.g. BMI and smoking status) and their 95% Confidence Intervals (95%CI) were obtained at each wave from multivariable Poisson models.
Results
Prevalence of depression varied with age (10.0% at age 26, 7.8% at age 38 and 18.3% at age 46) as did prevalence of pMM (37% at age 26, 15.6% at age 34, and 20.2% at age 46). A non-linear trend in the prevalence both of depression and pMM was observed with a decrease from age 26 to age 38 (34 for pMM) followed by a consistent increment to age 46. In all ages depression was significantly associated with pMM the magnitude ranging from PR: 1.52 (95%CI 1.41-1.65) at age 26 to PR: 1.96 (95%CI 1.72-2.23) at age 38.
Conclusions
There is consistent association between the prevalence of depression and pMM over different ages during adulthood. The non-linear pattern suggests differences in the type of conditions contributing to pMM at different ages (non-chronic in young adulthood vs chronic from middle adulthood). Further research on clusters and trajectories of different conditions over life course might be valuable to understand the association between depression and pMM.
Key messages
There is consistent association between the prevalence of depression and pMM over different ages during adulthood. They could be differences in the type of conditions contributing to depression related pMM at different ages (non-chronic in young adulthood vs chronic from middle adulthood).
Collapse
Affiliation(s)
- J Arias de la Torre
- King's College London, London, UK
- CIBER Epidemiology and Public Health, Madrid, Spain
| | | | | | - JAlonso
- CIBER Epidemiology and Public Health, Madrid, Spain
- Hospital del Mar Medical Research Institute, Barcelona, Spain
- Pompeu Fabra University, Barcelona, Spain
| | - M Prina
- King's College London, London, UK
| | - S Hatch
- King's College London, London, UK
| | - L Rayner
- King's College London, London, UK
| | | | - M Hotopf
- King's College London, London, UK
- South London and Maudsley NHS Foundation Trust, London, UK
| | - ADregan
- King's College London, London, UK
| |
Collapse
|